Committee advances bill protecting 340B contract‑pharmacy access; transparency measure on 340B laid over for further action

Two 340B‑related bills dominated the committee’s late‑night session: Senate Bill 71, aimed at preserving covered entities’ access to contract pharmacies and stopping manufacturers from restricting delivery, and Senate Bill 124, a separate measure that would require detailed reporting and limit how 340B savings may be used for patient‑level out‑of‑pocket reductions and charity care.

On SB 71, hospitals, rural clinics, community health centers and many contracted pharmacies told the committee that recent manufacturer restrictions on contract pharmacies have reduced patients’ local access to discounted medications and strained rural providers’ finances. Donald Moore of Pueblo Community Health Center said his clinic lost $1.7 million since 2022 because of manufacturer restrictions and that 3‑40B savings had allowed the health center to open a regional clinic and maintain reduced co‑payments for uninsured patients.

Proponents argued the federal 340B statute was intended to let safety‑net providers stretch scarce resources. Patients and public health advocates told personal stories of how 340B savings made cancer care, infusions and preventive medications affordable in communities distant from metropolitan centers. Many rural hospital witnesses said the savings directly fund local services that otherwise would be cut.

Pharmaceutical manufacturers and some employer and purchaser groups opposed SB 71. They argued the program has expanded well beyond congressional intent, that contract‑pharmacy arrangements have grown exponentially, and that the state law could conflict with federal statute and invite litigation. Several manufacturers pointed to federal court rulings and urged a federal solution, while buyer coalitions said the bill could shift drug costs into higher prices for other payers and urged stronger transparency and accountability rules.

After hours of testimony the committee adopted a set of sponsor amendments clarifying who is exempt, adding reporting language and technical cleanup; the committee reported SB 71 favorably to the Committee of the Whole. Opponents warned the state‑level remedy may trigger licensing and litigation disputes with manufacturers; proponents said the law is a necessary step to ensure patients keep local access.

Senate Bill 124 — the “Saving People Money on Prescription Medications Act” — was offered by a different sponsor team and focused on requiring hospitals that participate in 340B to direct a defined share of 340B savings to lower patient out‑of‑pocket costs and charity care, and to make those uses public. The bill drew strong patient and advocacy support for transparency and accountability, but hospitals, rural health centers and trade groups said the proposal would disrupt the multi‑facility, multi‑site financing that currently supports services and charity care across networks. The committee opened an amendment phase for SB 124; sponsors and opponents asked for time to negotiate before further action. The sponsor moved a technical floor amendment (L007) and the bill was laid over for continued consideration so members and stakeholders can review an offered change.

Why it matters: The 340B debate draws competing priorities — patient access to discounted drugs and local care versus market structure, manufacturer pricing and federal law — and the committee split reflected those tensions. SB 71 protects current covered entities’ contract‑pharmacy arrangements in Colorado; SB 124 attempts a state‑level transparency and usage mandate that supporters say is needed and opponents say could destabilize safety‑net financing.

What’s next: SB 71 was reported favorably to the Committee of the Whole; SB 124 remains in amendment phase with a sponsor amendment on the table and the committee agreed to lay further action over so parties can negotiate technical and policy changes.